GAMA
VRTX icon

Graticule Asia Macro Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Graticule Asia Macro Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-111,000
Closed -$8.82M – 89
2016
Q1 		$8.82M Buy
+111,000
New +$10M 0.69% 35

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Graticule Asia Macro Advisors's VRTX Position: Q4 2017 in Review

Graticule Asia Macro Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 41,300 shares — an estimated $6.28M sold.

Graticule Asia Macro Advisors first reported a position in VRTX in Q3 2015 and held it in 6 quarters. The position peaked at $8.92M in Q1 2016. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

  • Graticule Asia Macro Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 41,300 Vertex Pharmaceuticals shares in Q4 2017, an estimated $6.28M.
  • Graticule Asia Macro Advisors first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 6 quarters.
  • Graticule Asia Macro Advisors's Vertex Pharmaceuticals position peaked at $8.92M in Q1 2016.
  • 644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.